Although kinase inhibitors (for example, erlotinib and gefitinib) and monoclonal antibodies (such as cetuximab and nimotuzumab) that target the EGFR pathway have been widely used, the outcome of GBM patients remains poor [33]. This evidence concerns the gene EGFR and glioblastoma.